HCAT vs PINC

For growth investors, Health Catalyst, Inc.

(HCAT) is the stronger pick with 1. 5% revenue growth year-over-year, versus -10. 9% for Premier, Inc. (PINC). Premier, Inc. (PINC) offers the better valuation at 128. 5x trailing P/E (20. 8x forward), making it the more compelling value choice. Analysts rate Health Catalyst, Inc. (HCAT) a "Buy" — based on 22 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Health Catalyst, Inc.

is actually cheaper at 14. 1x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Premier, Inc.

(PINC) delivered a total return of -9. 2%, compared to -97. 0% for Health Catalyst, Inc. (HCAT). Over 10 years, the gap is even starker: PINC returned -4. 6% versus HCAT's -95. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Premier, Inc.

(PINC) is the lower-risk stock at 0. 07β versus Health Catalyst, Inc. 's 2. 05β — meaning HCAT is approximately 2781% more volatile than PINC relative to the S&P 500. On balance sheet safety, Health Catalyst, Inc. (HCAT) carries a lower debt/equity ratio of 8% versus 18% for Premier, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Health Catalyst, Inc.

(HCAT) is pulling ahead at 1. 5% versus -10. 9% for Premier, Inc. (PINC). On earnings-per-share growth, the picture is similar: Premier, Inc. grew EPS -78. 8% year-over-year, compared to -121. 7% for Health Catalyst, Inc.. Over a 3-year CAGR, HCAT leads at 4. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Premier, Inc.

(PINC) is the more profitable company, earning 2. 0% net margin versus -57. 2% for Health Catalyst, Inc. — meaning it keeps 2. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PINC leads at 0. 1% versus -51. 7% for HCAT. At the gross margin level — before operating expenses — PINC leads at 73. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Health Catalyst, Inc.

(HCAT) trades at 14. 1x forward P/E versus 20. 8x for Premier, Inc. — 6. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for HCAT: 57. 2% to $2. 50.

In this comparison, PINC (3.

0% yield) pays a dividend. HCAT does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Premier, Inc.

(PINC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 07), 3. 0% yield). Health Catalyst, Inc. (HCAT) carries a higher beta of 2. 05 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PINC: -4. 6%, HCAT: -95. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

PINC pays a dividend while HCAT does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.